Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 9, 1999, Pages 2251-2262

  Lupu, Cristina ^a   Poulsen, Emma ^a   Roquefeuil, Sylvie ^a   Westmuckett, Andrew D ^a   Kakkar, Vijay V ^a   Lupu, Florea ^a  

^a THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

Author keywords

Caveolae; Human endothelial cells; Low molecular weight heparin; Tissue factor pathway inhibitor; Unfractionated heparin

Indexed keywords

BLOOD CLOTTING FACTOR 7A; DALTEPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MESSENGER RNA; PHORBOL ESTER; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANTICOAGULATION; ARTICLE; CELL CULTURE; CELL MEMBRANE; CELLULAR DISTRIBUTION; ENDOTHELIUM CELL; GENE EXPRESSION; GLYCOCALYX; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS;

EID: 0032826248     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.9.2251     Document Type: Article

References (57)

1. Stern D, Handley D, Nawroth PP. Endothelium and the regulation of coagulation. In: Simionescu N, Simionescu M, eds. Endothelial Cell Biology in Health and Disease. New York, NY: Plenum Press; 1988: 275-306.
2. Pearson JD. Endothelial cell function and thrombosis. Baillieres Clin Haematol. 1994;7:441-452.
3. Broze GJ Jr. The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin Hematol. 1992;29:159-169.
4. Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA Jr. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med. 1984;160:618-623.
5. Brox JH, Osterud B, Bjorklid E, Fenton JW II. Production and availability of thromboplastin in endothelial cells: effects of thrombin, endotoxin and platelets. Br J Haematol. 1984;57:239-246.
6. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med. 1986;163:740-745.
7. Drake TA, Cheng J, Chang A, Taylor FB Jr. Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal E coli sepsis. Am J Pathol. 1993;142:1458-1470.
8. Contrino J, Hair G, Schmeizl M, Rickles F, Kreutzeur D. In situ characterization of antigenic and functional tissue factor expression in human tumors utilizing monoclonal antibodies and recombinant factor VIIa as probes. Am J Pathol. 1994;145:1315-1322.
9. Broze GJ Jr, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood. 1988;71:335-343.
10. Schwartz AL, Broze GJ Jr. Tissue factor pathway inhibitor endocytosis. Trends Cardiovasc Med. 1997;7:234-239.
11. Huang ZF, Wun TC, Broze GJ Jr. Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem. 1993;268:26950-26955.
12. Huang ZF, Higuchi D, Lasky N, Broze GJ Jr. Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood. 1997;90:944-951.
13. Lesnik P, Vonica A, Guerin M, Moreau M, Chapman MJ. Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a). Arterioscler Thromb. 1993;13:1066-1075.
14. Novotny WF, Girard TJ, Miletich JP, Broze GJ Jr. Purification and characterization of the lipoprotein-associaled coagulation inhibitor from human plasma. J Biol Chem. 1989;264:18832-18837.
15. Broze GJ Jr, Lange GW, Duffin KL, MacPhail L. Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coagul Fibrinolysis. 1994; 5:551-559.
16. Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci U S A. 1990;87:8869-8873.
17. Abildgaard U. Heparin/low molecular weight heparin and tissue factor pathway inhibitor. Haemostasis. 1993;23(suppl 1):103-106.
18. Lupu C, Lupu F, Dennehy U, Kakkar VV, Scully MF. Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture. Arterioscler Thromb Vasc Biol. 1995;15:2055-2062.
19. Hansen JB, Olsen R, Webster P. Association of tissue factor pathway inhibitor with human umbilical vein endothelial cells. Blood. 1997;90: 3568-3578.
20. Lupu C, Goodwin CA, Westmuckett AD, Emeis JJ, Scully MF, Kakkar VV, Lupu F. Tissue factor pathway inhibitor in endothelial cells colocalizes with glycolipid microdomains/caveolae: regulatory mechanism(s) of the anticoagulant properties of the endothelium. Arterioscler Thromb Vasc Biol. 1997;17:2964-2974.
21. Simionescu N, Simionescu M, Palade GE. Differentiated microdomains on the luminal surface of the capillary endothelium, I: preferential distribution of anionic sites. J Cell Biol. 1981;90:605-613.
22. Simionescu M, Simionescu N, Silbert JE, Palade GE. Differentiated microdomains on the luminal surface of the capillary endothelium, II: partial characterization of their anionic sites. J Cell Biol. 1981;90: 614-621.
23. Sevinsky JR, Rao LVM, Ruf W. Ligand-induced protease receptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway. J Cell Biol. 1996;133:293-304.
24. Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ Jr. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood. 1991;78:387-393.
25. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res. 1988;50: 803-813.
26. Hull RD, Raskob GE, Hirsch J, Jay RM, Leclerc JR, Geerts WH, Bosenbloom D, Sackett DL, Anderson C, Harrison L, Gent M. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1986;315:1109-1114.
27. Neri Serneri GG, Gensini GF, Poggesi L, Trotta F, Modesti PA, Boddi M, Ieri A, Margheri M, Casolo GC, Bini M, Rostagno C, Carnovali M, Abbate R. Effect of heparin, aspirin, or alteplase in reduction of myocardial ischemia in refractory unstable angina. Lancet. 1990;335: 615-618.
28. Bourin MC, Lindahl U. Glycosaminoglycans and the regulation of blood coagulation. Biochem J. 1993;289:313-330.
29. Tollefsen DM. Insight into the mechanism of action of heparin cofactor II. Thromb Haemost. 1995;74:1209-1214.
30. Novotny WF, Palmier M, Wun TC, Broze GJ Jr, Miletich JP. Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood. 1991;78:394-400.
31. Lindahl AK, Jacobsen PB, Sandset PM, Abildgaard U. Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients. Blood Coagul Fibrinolysis. 1991;2:713-721.
32. Edgell CJS, McDonald CG, Graham JB. Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc Natl Acad Sci U S A. 1983;80:3734-3737.
33. Levin EG, Marotti KR, Santell L. Protein kinase C and the stimulation of tissue plasminogen activator release from human endothelial cells: dependence on the elevation of messenger RNA. J Biol Chem. 1989;264: 16030-16036.
34. Kyhse-Anderson J. Electroblotting of multiple gels: a simple apparatus without buffer tank for rapid transfer of proteins from polyacrylamide to nitrocellulose. J Biochem Biophys Methods. 1984;10:203-209.
35. Vincent S, Marty L, Fort P. S26 ribosomal protein RNA: an invariant control for gene regulation experiments in eukaryotic cells and tissues. Nucleic Acids Res. 1993;21:1498-1503.
36. Kumar A, Koenig KB, Johnson AR, Idell S. Expression and assembly of procoagulant complexes by human pleural mesothelial cells. Thromb Haemost. 1994;71:587-592.
37. Girard TJ, Warren LA, Novotny WF, Bejcek BE, Miletich JP, Broze GJ Jr. Identification of the 1.4 KB and 4.0 KB messages for the lipoprotein associated coagulation inhibitor and expression of the encoded protein. Thromb Res. 1989;55:37-50.
38. Smart EJ, Ying YS, Anderson RGW. Hormonal regulation of caveolae internalization. J Cell Biol. 1995;131:929-938.
39. Lindahl AK, Sandset PM, Abildgaard U. The present status of tissue factor pathway inhibitor [review]. Blood Coagul Fibrinolysis. 1992;3: 439-449.
40. Valentin S, Larnkjer A, Ostergaard P, Nielsen JI, Nordfang O. Characterization of the binding between tissue factor pathway inhibitor and glycosaminoglycans. Thromb Res. 1994;75:173-183.
41. Valentin S, Nordfang O, Bregengard C, Wildgoose P. Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins. Blood Coagul Fibrinolysis. 1993;4:713-720.
42. Hampton YR, Koning A, Wright R, Rine J. In vivo examination of membrane protein localization and degradation with green fluorescent protein. Proc Natl Acad Sci U S A. 1996;93:828-833.
43. Simionescu M, Simionescu N. Endothelial transport of macromolecules: transcytosis and endocytosis. Cell Biol Rev. 1991;25:1-80,
44. Anderson RGW. Caveolae: where incoming and outgoing messengers meet [review]. Proc Natl Acad Sci U S A. 1993;90:10909-10913.
45. Stahl A, Mueller BM. The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae. J Cell Biol. 1995;129: 335-344.
46. Fujimoto T, Miyawaki A, Mikoshiba K. Inositol 1,4,5-trisphosphate receptor-like protein in plasmalemmal caveolae is linked to actin filaments. J Cell Sci. 1995;108:7-15.
47. Iversen N, Sandset PM, Abildgaard U, Torjesen PA. Binding of tissue factor pathway inhibitor to cultured endothelial cells: influence of glycosaminoglycans. Thromb Res. 1996;84:267-278.
48. Jesty J, Lorenz A, Rodriguez J, Wun TC. Initiation of the tissue factor pathway of coagulation in the presence of heparin: control by antithrombin III and tissue factor pathway inhibitor. Blood. 1996;87: 2301-2307.
49. Hansen JB, Sandset PM, Huseby KR, Huseby NE, Nordoy A. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man. Thromb Haemost. 1996;76:703-709.
50. van Rijn JLML, Trillou M, Mardiguian J, Tobelem G, Caen J. Selective binding of heparins to human endothelial cells: implications for pharmacokinetics. Thromb Res. 1987;45:211-222.
51. Patton WA II, Granzow CA, Getts LA, Thomas SC, Zotter LM, Gunzel KA, Lowe-Krentz LJ. Identification of a heparin-binding protein using monoclonal antibodies that block heparin binding to porcine aortic endothelial cells. Biochem J. 1995;311:461-469.
52. Au YPT, Kenagy RD, Clowes AW. Heparin selectively inhibits the transcription of tissue-type plasminogen activator in primate arterial smooth muscle cells during mitogenesis. J Biol Chem. 1992;267: 3438-3444.
53. van der Logt CPE, Reitsma PH, Bertina RM. Intron-exon organization of the human gene coding for the lipoprotein-associated coagulation inhibitor: the factor Xa dependent inhibitor of the extrinsic pathway of coagulation. Biochemistry. 1991;30:1571-1577.
54. Smart EJ, Foster DC, Ying Y-S, Kamen BA, Anderson RGW. Protein kinase C activators inhibit receptor-mediated potòcytosis by preventing internalization of caveolae. J Cell Biol. 1994;124:307-313.
55. Mineo C, Ying Y-S, Chapline C, Jaken S, Anderson RGW. Targeting of protein kinase C-α to caveolae. J Cell Biol. 1998;141:601-610.
56. Wright TC, Pukac LA, Castellot JJ, Karnovsky MJ, Levine RA, Kim-Park H-Y, Campisi J. Heparin suppresses the induction of c-fos and c-myc mRNA in murine fibroblasts by selective inhibition of a protein kinase C-dependent pathway. Proc Natl Acad Sci U S A. 1989;86:3199-3203.
57. Conricode KM, Brewer KA, Exton JH. Activation of phospholipase D by protein kinase C: evidence for a phosphorylation-independent mechanism. J Biol Chem. 1992;267:7199-7202.